-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9

Benzinga·10/29/2026 22:25:35
Listen to the news
Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.